Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF35700 cardiac repolarization study in schizophrenia
NCT02901587Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Sep 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lu af35700 in schizophrenia and schizoaffective disorder (3 arms), sponsored by Lundbeck. Primary endpoint: Change from time-matched baseline in QTcF at Day 42. Started Sep 2016; status: completed.
02
Drugs
lu af35700
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02901587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901587.